279
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Mechanism-based drug repurposing for (rare) diseases – Precision Medicine at its best

      Published
      proceedings-article
      Bookmark

            Abstract

            Precision Medicine offers great promise to advance diagnostic and treatment option for patients based on individual characteristics, profound molecular and pathway knowledge and consequently objective diagnostic means based on biomarker signatures. So far, the implementation was hampered by many factors such as current disease definitions. These are mostly symptom or organ based or an agglomeration of symptoms named after the physician who first identified the disease.

            These facts render today’s disease definitions and diagnostics rather subjective and molecular basis or mechanism for the optimal treatment decision are lacking. This is a fundamental issue for drug development as many drugs target a certain set of symptom and not well-defined molecular mechanisms, therefore benefitting only subsets of patients.

            Moreover, this hampers drug repurposing as precise mechanisms need to be identified to be targeted by a certain drug or compound. Mechanism-based repurposing can have a dramatic benefit as this reduces cost, time for development and renders coverage of rare diseases potentially much easier.

            A key role plays an in-depth molecular characterization and biomarker signatures as well as software supported integration into the diagnostic workflow. This enables early and precise diagnosis of a disease as well as patient stratification according to their individual therapy responses and optimal doses required.

            Sciomics is part of the Horizon2020 MCDS-Therapy project having the aim of repurposing Carbamazipine as a treatment for “metaphyseal chondrodysplasia type Schmid (MCDS)”, a rare bone growth disorder. An in-depth protein profiling was performed using mouse models and patient samples, comparing the model to the human situation, elucidating the molecular disease phenotype as well as identifying biomarker candidates.

            Content

            Author and article information

            Conference
            ScienceOpen
            29 August 2022
            Affiliations
            [1 ] Sciomics GmbH, Neckargemünd (Germany)
            Author notes
            Author information
            https://orcid.org/0000-0002-2043-2789
            Article
            10.14293/S2199-1006.1.SOR-.PPPPTMXA.v1
            d780b3af-9846-42d3-a9e6-c76a7ca4533c

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            : 29 August 2022

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Protein profiling, Precision medicine, Metaphyseal chondrodysplasia type Schmid, MCDS, Drug repurposing, Carbamazipine

            Comments

            Comment on this article